Generic and Biosimilar Medicines Industries Welcome Ontario Government’s Investment in Next Phase of Life Sciences Strategy
The CGPA and its Biosimilars Canada division welcome the Ontario government’s announcement of a $146 million investment in the next phase of its Life Sciences Strategy to help position the province as a global leader in life sciences.